Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mark Guinan Insider Profile
4 Followers
Mark Guinan, EVP & CFO at Quest Diagnostics, holds 73.58K shares in Quest Diagnostics (Ticker: DGX), holds ― shares in Myovant Sciences (Ticker: MYOV), holds 19.04K shares in Hill-Rom (Ticker: HRC).
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+7.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Mark Guinan holds in companies
Most Profitable Insider Trade
The most profitable trade made by Mark Guinan
Mark Guinan's Trading History
Quest Diagnostics
Jun 10, 2020
EVP & CFO
Uninformative Sell
8.51M
$9.18M
Myovant Sciences
―
Director
―
―
Hill-Rom
Dec 18, 2012
SVP & CFO
Uninformative Buy
93.40K
$1.82M
List of latest transactions for each holding click on a transaction to see Mark Guinan's performance on stock
You May Also Like
Mark Guinan insider profile FAQ
What is the percentage of profitable transactions made by Mark Guinan?
The percentage of profitable transactions made by Mark Guinan is 50%.
What is the average return per transaction made by Mark Guinan?
The average return per transaction made by Mark Guinan is 7.80%.
What stocks does Mark Guinan hold?
Mark Guinan holds: DGX, MYOV, HRC stocks.
What was Mark Guinan’s latest transaction?
Mark Guinan latest transaction was an Uninformative Sell of $8.51M.
What was Mark Guinan's most profitable transaction?
Mark Guinan’s most profitable transaction was an Informative Buy of DGX stock on May 7, 2014. The return on the trade was 29.70%.
What is Mark Guinan's role in Quest Diagnostics?
Mark Guinan's role in Quest Diagnostics is EVP & CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.